<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04479748</url>
  </required_header>
  <id_info>
    <org_study_id>DEXTENZA</org_study_id>
    <nct_id>NCT04479748</nct_id>
  </id_info>
  <brief_title>DEXTENZA Compared to Topical Steroid Therapy Prior to Cataract Surgery in Patients Who Receive Premium Intraocular Lenses</brief_title>
  <official_title>DEXTENZA Compared to Topical Steroid Therapy Prior to Cataract Surgery in Patients Who Receive Premium Intraocular Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prism Vision Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prism Vision Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators seek to assess the effect of pre-operative and continued post-operative&#xD;
      corticosteroid use on pain, patient preference, visual outcomes, and change in objective&#xD;
      quantifiable biological parameters in patients undergoing bilateral cataract surgery with&#xD;
      premium intraocular lens implantation with or without baseline ocular surface disease.&#xD;
&#xD;
      Patient's first eye scheduled for surgery will receive an intracanalicular insertion of&#xD;
      DEXTENZA (dexamethasone release profile of QID, TID, BID, QD, over 30 days; study eye). The&#xD;
      fellow-eye will receive topical prednisolone acetate 1% (tapering schedule of QID, TID, BID,&#xD;
      QD over 30 days). The fellow-eye design in n=30 patients (60 eyes) allows for balance in&#xD;
      patient baseline demographic and systemic characteristics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scale</measure>
    <time_frame>30 days</time_frame>
    <description>Proportion of eyes with absence of pain as measured by pain scale (pain score = 0) from Baseline over each time point through Day 30.&#xD;
Subjects will use the Ocular Pain Assessment scale. A 0-10 point scale, where 0 is the least pain and 10 is the greatest pain, subjects will be asked to rank their level of pain.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Dextenza insert</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient's first eye scheduled for surgery will receive an intracanalicular insertion of DEXTENZA (dexamethasone release profile of QID, TID, BID, QD, over 30 days; study eye).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fellow-eye</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The fellow-eye will receive topical prednisolone acetate 1% (tapering schedule of QID, TID, BID, QD over 30 days). The fellow-eye design in n=30 patients (60 eyes) allows for balance in patient baseline demographic and systemic characteristics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Treatment of pain and inflammation following ophthalmic surgery</description>
    <arm_group_label>Dextenza insert</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate 1% Oph Susp</intervention_name>
    <description>Topical steroid</description>
    <arm_group_label>Fellow-eye</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Age 18 or greater with plans to undergo bilateral clear cornea cataract surgery with&#xD;
             phacoemulsification and implantation of a premium posterior chamber IOL&#xD;
&#xD;
               -  Schirmer's test score (anesthetized) ≥ 5 mm at Screening in either eye.&#xD;
&#xD;
               -  TBUT ≤ 7 seconds at Screening or Baseline in either eye.&#xD;
&#xD;
               -  All subjects must provide signed written consent prior to participation in any&#xD;
                  study-related procedures. Able to comply with study requirements and visit&#xD;
                  schedule.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  revious corneal surgery or pathology&#xD;
&#xD;
               -  Active or history of chronic or recurrent inflammatory eye disease in either eye&#xD;
&#xD;
               -  Ocular pain in either eye&#xD;
&#xD;
               -  Proliferative diabetic retinopathy in either eye&#xD;
&#xD;
               -  Significant macular pathology detected on macular optical coherence tomography&#xD;
                  evaluation at the screening visit in either eye&#xD;
&#xD;
               -  Laser or incisional ocular surgery during the study period and 6 months prior in&#xD;
                  either eye&#xD;
&#xD;
               -  Prescription and OTC ophthalmic mast cell stabilizers and antihistamines within&#xD;
                  21 days prior to Screening and throughout the study period (systemic mast cell&#xD;
                  stabilizers are allowed, and systemic antihistamines are permitted)&#xD;
&#xD;
               -  Chronic daily use (defined as &gt; 7 consecutive days at the recommended dosing&#xD;
                  frequency) of systemic narcotics for any chronic pain syndrome (eg, fibromyalgia,&#xD;
                  rheumatoid arthritis, etc.) during the study period.&#xD;
&#xD;
               -  Ophthalmic artificial tear drop use within 2 hours prior to any study visit. Any&#xD;
                  OTC artificial tear (preserved or unpreserved) should be continued at the same&#xD;
                  frequency and with no change in drop brand.&#xD;
&#xD;
               -  Use of any topical prescription ophthalmic medications (including cyclosporine&#xD;
                  [Restasis®, Cequa®] or topical lifitegrast [Xiidra®], steroids, nonsteroidal&#xD;
                  anti- inflammatory drugs [NSAIDs], anti-glaucoma medications within 7 days or&#xD;
                  during study period&#xD;
&#xD;
               -  Participation in any drug or device clinical investigation within 30 days prior&#xD;
                  to entry into this study and/or during the period of study participation.&#xD;
&#xD;
               -  Corticosteroids (intranasal, inhaled, topical dermatological, and perianal&#xD;
                  steroids) within 30 days prior to entry in the study are not permitted&#xD;
&#xD;
               -  Pregnant or breast-feeding women, women who wish to become pregnant during the&#xD;
                  length of study participation, or women of child-bearing potential.&#xD;
&#xD;
               -  Use of systemic NSAID greater than 375 mg per day.&#xD;
&#xD;
               -  Glaucoma or is on medications to treat glaucoma.&#xD;
&#xD;
               -  Ocular Hypertension, defined as IOP of &gt;21 mmHg, is on medications to treat&#xD;
                  hypertension or has a history of IOP spikes in either eye including&#xD;
                  steroid-related IOP increases.&#xD;
&#xD;
               -  Presence of nasolacrimal duct obstruction or history of cauterization of the&#xD;
                  Punctum.&#xD;
&#xD;
               -  Active epiphora or clinically significant dry eye syndrome.&#xD;
&#xD;
               -  Know allergy or sensitivity to the investigational product or its components.&#xD;
&#xD;
               -  The Investigator determines that the subject should not be included for reasons&#xD;
                  not already specified (e.g, systemic or other ocular disease/abnormality) if the&#xD;
                  health of the subject or the validity of the study outcomes may be compromised by&#xD;
                  the subject's enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Janie Flores</last_name>
    <phone>(856) 691-8188</phone>
    <phone_ext>228</phone_ext>
    <email>jflores@sjeyeassociates.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eye Associates of Vineland</name>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <zip>08361</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janie Flores</last_name>
      <phone>856-691-8188</phone>
      <phone_ext>228</phone_ext>
      <email>jflores@sjeyeassociates.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prism Vision Group</investigator_affiliation>
    <investigator_full_name>Dr. Sydney Tyson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

